- About us ▼
- Information ▼
- Meetings/Events ▼
- How to find us
- Guest Speaker Profiles ▶
- June 2018 - Geraldine Barnard
- August 2018 - Yvonne Brylka-Mee
- September 2018 - Mr Hemant Nemede
- October 2018 - Sue Boyes
- November 2018 - Jacqui Barnett
- December 2018 - James Skeggs
- February 2019 - Lucie Rought
- March 2019 - Northamptonshire Carers
- April 2019 - Yvonne Brylka-Mee
- May 2019 - Lynne Gordon
- August 2020 - Andrew Gabriel
- April 2021 - Chris Kent
- May 2021 - Kirsty Murphy
- Calendar ▶
- Committee Meetings - Feedback ▶
- Contacting Us
- St John's
- Donations ▼
NEW HYDROGEL SPACER HELPS TO REDUCE SIDE-EFFECTS FOR PROSTATE CANCER PATIENTS
SpaceOAR® Hydrogel has been designed to reduce radiation exposure to the organs surrounding the prostate. This, in turn, reduces the potential long-term side-effects of radiotherapy such as rectal bleeding, bowel dysfunction, urinary incontinence and potency.1,2,3
SpaceOAR® hydrogel is a soft gel that creates space between the prostate and rectum. Space is important – it helps maximise the radiation dose to the prostate gland and avoid unnecessary irradiation of surrounding tissue, minimising harmful side-effects.
Through a straightforward, minimally invasive procedure, the gel temporarily positions the rectal wall away from the prostate during radiotherapy treatment for prostate cancer. The gel, which is water absorbable, remains in place for three to six months, after which it is naturally absorbed by the patient’s body.
Image 1: SpaceOAR® hydrogel pushes the rectum out of the high dose radiation field.
SpaceOAR® hydrogel has been implanted in over 25,000 men worldwide and evaluated in over 60 publications. SpaceOAR has been shown to be safe and effective in reducing radiation side effects. The patient benefits at a median follow-up of 3 years include:
- A reduction in late Grade 1+ rectal toxicity from radiation
(9.2% control vs 2% treated)1
- A reduction in urinary incontinence from 15-37 months
(19.6% control vs 4.3% treated)1
- A reduction in bowel Quality of Life declines (twice the minimally clinically detectable change)
(20.5% control vs 5.4% treated)1
- Potent men were more likely to retain erections sufficient for intercourse
(37.5% control vs 66.7% treated)2
If you want more information then we have explantory leaflets available or have a look at their web site www.spaceoarcom
Monthly Zoom Meeting: Tuesday 4th May 2021: meeting will open at 7pm with a start at 7:30pm.
Invitations will be sent to all members on Monday 3rd May. Please email us if you are not contacted but wish to take part.
Northampton General Hospital Information Webinars. here is the link: